armillarisin a + dexamethasone

Armillarisin A + dexamethasone is a combination therapy consisting of armillarisin A, a coumarin derivative with reported anti-inflammatory and immunomodulatory properties, and dexamethasone, a synthetic corticosteroid. This combination has been studied for the treatment of ulcerative colitis via enema administration. Armillarisin A may exert its effects by modulating immune responses, specifically increasing serum IL-4 and decreasing IL-1β levels, which are associated with inflammation in ulcerative colitis. Dexamethasone acts as an anti-inflammatory and immunosuppressant by binding to glucocorticoid receptors and altering gene expression to reduce inflammatory cytokine production[1][3][5]. The combination aims to enhance therapeutic efficacy in reducing inflammation compared to either agent alone.